Vanderbilt registers Phase 2 Lazarus trial testing IT therapy to prevent ICANS after CAR T
Gilead-collaborated trial will test intrathecal cytarabine and hydrocortisone against ICANS following axi-cel and brexu-cel in non-Hodgkin lymphoma.
One new trial entered the registry this week involving Gilead's CAR T therapies.
- A Phase 2 trial called "Lazarus" is not yet recruiting, sponsored by Vanderbilt-Ingram Cancer Center with Gilead Sciences as a collaborator. The trial aims to reduce the duration of ICANS and incidence of grade 3 or greater ICANS in participants who receive axi-cel.1 The study plans to enroll 59 participants and will test intrathecal hydrocortisone 100mg plus cytarabine 100mg at onset of grade 1/2 ICANS1 following brexu-cel or axi-cel infusion, with an estimated primary completion date of October 2029.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.